Dermata Therapeutics Files 2024 10-K, Highlights Cybersecurity
Ticker: DRMAW · Form: 10-K · Filed: Mar 17, 2025 · CIK: 1853816
| Field | Detail |
|---|---|
| Company | Dermata Therapeutics, Inc. (DRMAW) |
| Form Type | 10-K |
| Filed Date | Mar 17, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, cybersecurity, pharmaceuticals
TL;DR
Dermata's 2024 10-K is in. They're focused on limiting sensitive data to manage cyber risks via outsourced IT.
AI Summary
Dermata Therapeutics, Inc. filed its 2024 10-K on March 17, 2025, reporting on its fiscal year ending December 31, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector and is headquartered in San Diego, California. A key focus highlighted in the filing is their cybersecurity risk management program, which involves data segregation, safeguards, and documented procedures, with a strategy to minimize risk by limiting sensitive data within their enterprise through outsourced IT services.
Why It Matters
This filing provides investors with a comprehensive overview of Dermata Therapeutics' financial health and operational strategies for the fiscal year 2024, including their approach to managing critical cybersecurity risks.
Risk Assessment
Risk Level: medium — The filing details cybersecurity risks and management strategies, indicating a medium level of concern due to the inherent risks in handling sensitive data within the pharmaceutical sector.
Key Numbers
- 250000000 — Authorized Shares (Indicates potential for future equity financing)
- 2517768 — Net Sales (Revenue generated during the fiscal year)
- 261998 — Cost of Revenue (Direct costs associated with generating revenue)
- 1526232 — Operating Expenses (Costs incurred in normal business operations)
Key Players & Entities
- Dermata Therapeutics, Inc. (company) — Filer of the 10-K
- 2024 (date) — Fiscal year end
- March 17, 2025 (date) — Filing date
- San Diego, California (location) — Company headquarters
- Pharmaceutical Preparations (industry) — Company's SIC code
FAQ
What is Dermata Therapeutics' primary strategy for minimizing cybersecurity risk?
Dermata's primary strategy for minimizing cybersecurity risk is limiting the amount of sensitive data within their enterprise by fully outsourcing their IT environment to expert third-party software-as-a-service, human resource, and clinical providers.
When was Dermata Therapeutics' 2024 10-K filed?
Dermata Therapeutics' 2024 10-K was filed on March 17, 2025.
What is Dermata Therapeutics' fiscal year end?
Dermata Therapeutics' fiscal year end is December 31.
What industry does Dermata Therapeutics operate in?
Dermata Therapeutics operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
Where is Dermata Therapeutics headquartered?
Dermata Therapeutics is headquartered at 3525 Del Mar Heights Rd., #322, San Diego, CA 92130.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 17, 2025 regarding Dermata Therapeutics, Inc. (DRMAW).